MDCK-MRP2 - Dkfz

Forschungsschwerpunkt C
Krebsrisikofaktoren und Krebsprävention
[40] Fröhling S., Schlenk R.F., Breitruck J., Benner A.,
Kreitmeier S., Tobis K., Döhner H., Döhner K.: Prognostic significance
of activating FLT3 mutations in younger adults (16 to 60
years) with acute myeloid leukemia and normal cytogenetics: a
study of the AML study group Ulm. Onkol. 25(S4), p.218 (769),
2002.
[41] Gastl G., Berdel W., Edler L., Jaehde U., Port R.E., Mross
K.B., Scheulen M.E., Sindermann H., Dittrich C.: Standard operating
procedures for clinical trials of the CESAR - Central European
Society for Anticancer Drug Research - EWIV. Onkol. 26
(Suppl.6) , 2003.
[42] Geisler I., Kopp-Schneider A.: Modeling the formation
and growth of radiation induced liver focal lesions. pp.68-69,
2002. Freiburg, Germany, Int.Biometr.Soc. Proceedings XXIth
International Biometric Conference, July 21-26.
[43] Goldschmidt H., Sonneveld P., Cremer F.W., van der Holt B.,
Westveer P., Breitkreutz I., Benner A., Glasmacher A., Schmidt-
Wolf I.G.D., Martin H., Hölzer D., Ho A.D., Lokhorst H.M.: Joint
HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide
as part of a high-dose therapy regimen and as maintenance
treatment for newly diagnosed myeloma patients. Ann.Hemtol.
82 654-659, 2003.
[44] Görner M., Weber-Nordt R., Höpfner S., Benner A., Luft
T., Ho A.D.: Addition of a low fixed number of CD3+ cells to
CD34-enriched allografts: effects on engraftment, graft-versushost
disease, and survival after related und unrelated peripheral
stem cell transplantation. J.Hematother.Stem Cell Res. 12 (3)
309-320, 2003.
[45] Hamann U., Liu X., Lange S., Ulmer H.U., Benner A., Scott
R.J.: Contribution of BRCA2 germline mutations to hereditary
breast/ovarian cancer in Germany. J.Med.Genet. 39 (3) E12,
2002.
[46] Hauer K., Hildebrandt W., Sehl Y., Edler L., Oster P., Dröge
W.: Improvement in muscular performance and decrease in tumor
necrosis factor level in old age after antioxidant treatment.
J.Mol.Med. 81 (2) 118-125, 2003.
[47] Heinzl H., Edler L.: Assessing uncertainty in a toxicokinetic
model for human lifetime exposure to TCDD.
Organohalogen Comp. 59 355-358, 2002.
[48] Heinzl H., Edler L.: Evaluating and assessing uncertainty
of large-scaled statistical analyses exemplified at the Boehringer
TCDD cohort. Paper #52, pp.87-94, 2003. Amsterdam, Netherlands,
Inst.Res.Extramural Med., VU Univ. Proc. of the 2nd
Workshop on Research Methodoloy http://www.knaw.nl/
rm2003/
[49] Hofheinz R., Hartung G., Samel S., Hochhaus A., Hehlmann
R., Pilz L., Queisser W.: Second-line treatment of advanced
colorectal cancer with irinotecan, 24-hour high-dose 5-fluorouracil
(HD-5-FU) and folinic acid (FA) after failure for HD-5-FU/FA.
J.Cancer Res.Clin.Oncol. 128(Suppl.1), p.80 (P408), 2002.
[50] Hofheinz R.D., Wenz F., Willecke F., Post S., Edler L.,
Hartung G., Hochhaus A.: Randomized phase III study of adjuvant
radiochemotherapy with Capecitabine versus 5-Fluorouracil
(5-FU) in rectal carcinoma. Onkol. 25(6), p.593, 2002.
[51] Hofmann U., Szedlak M., Rittgen W., Jung E.G.,
Schadendorf D.: Primary staging and follow-up in melanoma patients
- monocenter evaluation of methods, costs and patient
survival. Brit.J.Cancer 87 (2) 151-157, 2002.
[52] Höpfner S., Görner M., Benner A., Henning P., Ho A.D.:
Unrelated donor transplantation after reduced intensity conditioning
as an approach for patients lacking related donors for allogeneic
stem cell transplantation. J.Hematother.Stem Cell Res.
12 (3) 331-339, 2003.
[53] Höpfner S., Görner M., Benner A., Ho A.D.: Nonmyeloablative
transplantation - comparison of related versus unrelated
donors. Onkol. 25(S4), p.97 (336), 2002.
C060
Biostatistik
[54] Ittrich C., Deml E., Österle D., Küttler K., Mellert W.,
Brendler-Schwaab S., Enzmann H., Schladt L., Bannasch P.,
Härtel T., Mönnikes O., Schwarz M., Kopp-Schneider A.:
Prevalidation of a rat liver foci bioassay (RLFB) based on results
from 1600 rats: a study report. Toxicol.Pathol. 31 (1) 60-79,
2003.
[55] Kienle D., Kröber A., Katzenberger T., Otto G., Leupolt E.,
Barth T., Möller P., Benner A., Habermann A., Müller-Hermelink
H.K., Bentz M., Lichter P., Döhner H., Stilgenbauer S.: VH mutation
status and VDJ rearrangement structure in mantle cell lymphoma:
correlation with genomic aberrations, clinical characteristics
and outcome. Onkol. 26(S5), p.162 (P825), 2003.
[56] Kienle D., Kröber A., Katzenberger T., Otto G., Leupolt E.,
Barth T.F.E., Möller P., Benner A., Habermann A., Müller-
Hermelink H.K., Bentz M., Lichter P., Döhner H., Stilgenbauer S.:
VH mutation status and VDJ rearrangement structure in mantle
cell lymphoma: correlation with genomic aberrations, clinical characteristics,
and outcome. Blood 102 (8) 3003-3009, 2003.
[57] Kienle P., Buhl K., Kuntz C., Dux M., Hartmann C., Benner
A., Herfarth C., Lehnert T.: Prospective comparison of endoscopy,
endosonography and computed tomography for staging of
tumours of the oesophagus and gastric cardia. Digestion 66 (4)
230-236, 2002.
[58] Kienle P., Koch M., Autschbach F., Benner A., Treiber M.,
Wannenmacher M., v.Knebel-Doeberitz M., Buchler M., Herfarth
C., Weitz J.: Decreased detection rate of disseminated tumor
cells of rectal cancer patients after preoperative chemoradiation:
a first step towards a molecular surrogate marker for neoadjuvant
treatment in colorectal cancer. Ann.Surg. 238 (3) 324-
331, 2003.
[59] Kienle P., Weitz J., Benner A., Herfarth C., Schmidt J.:
Laparoscopically assisted colectomy and ileoanal pouch procedure
with and without protective ileostomy. Surg.Endosc. 17 (5)
716-720, 2003.
[60] Kienle P., Weitz J., Koch M., Benner A., Herfarth C.,
Schmidt J.: Biofeedback versus electrostimulation in treatment of
anal sphincter insufficiency. Digest.Dis.Sci. 48 (8) 1607-1613,
2003.
[61] Kim B.S., Park J.J., Edler L., Fournier D.v., Haase W.,
Sautter-Bihl M.L., Gotzes F., Thielmann H.W.: The second derivative
of the dose-time-response surface as a measure of DNA repair
kinetics in the comet assay. Environmetrics 14 169-182,
2003.
[62] Kim B.S., Park J.J., Edler L., v.Fournier D., Haase W.,
Sautter-Bihl M.L., Gotzes F., Thielmann H.W.: New measure of
DNA repair in the single-cell gel electrophoresis (Comet) assay.
Environ.Mol.Mutagen. 40 50-56, 2002.
[63] Kinscherf R., Cafaltzis K., Röder F., Hildebrandt W., Edler
L., Deigner H.P., Breitkreutz R., Feussner G., Kreuzer J., Werle
E., Michel G., Metz J., Dröge W.: Cholesterol levels linked to abnormal
plasma thiol concentrations and thiol/disulfide redox status
in hyperlipidemic subjects. Free Radic.Bio.Med. 35 (10) 1286-
1292, 2003.
[64] Klaes R., Benner A., Friedrich T., Ridder R., Herrington S.,
Jenkins D., Kurman R.J., Schmidt D., Stoler M., Knebel-Doeberitz
M.v.: p16INK4a immunohistochemistry improves interobserver
agreement in the diagnosis of cervical intraepithelial neoplasia.
Am.J.Surg.Pathol. 26 (11) 1389-1399, 2002.
[65] Kopp-Schneider A.: Mechanistic carcinogenesis models in
quantitative risk assessment: potentials and limitations. pp.5-6,
2002. Freiburg, Germany, Int.Biometr.Soc. Proceedings XXIth
International Biometric Conference, July 21-26.
[66] Kopp-Schneider A., Geisler I., Edler L.: Complex
mechanistic carcinogenicity modeling. In: Endocrine disrupters
and carcinogenic risk assessment. IOS Press, 2002, pp.317-328.
[67] Korshunov A., Neben K., Wrobel G., Tews B., Benner A.,
Hahn M., Golanov A., Lichter P.: Gene expression patterns in
ependymomas correlate with tumor location, grade, and patient
age. Am.J.Pathol. 163 (5) 1721-1727, 2003.
DKFZ 2004: Wissenschaftlicher Ergebnisbericht 2002 - 2003
213